Medtrum spotlights 300U tubeless patch pump at DDG 2026

By AI, Created 7:36 AM UTC, May 27, 2026, /AGP/ – Medtrum used the 60th Diabetes Congress in Berlin to showcase its 300-unit tubeless patch pump and its TouchCare Nano connected diabetes system. The company says the larger-capacity pump is nearing availability in Germany and is designed to better serve people who need more insulin each day.

Why it matters: - The 300U tubeless patch pump is meant to help people who need higher daily insulin doses avoid more frequent reservoir changes. - Medtrum is tying pump capacity to a broader connected diabetes platform, not just a single device. - The showcase points to a push for more practical insulin delivery options for people with type 2 diabetes, severe insulin resistance and other complex insulin needs.

What happened: - Medtrum featured its 300-unit tubeless patch pump at the 60th Diabetes Congress in Berlin, also known as DDG 2026. - The booth message said, “300 Patch-Pumpe ist da!” — “The 300U patch pump is here.” - The showcase came ahead of the 300-unit tubeless patch pump’s upcoming availability in Germany. - Medtrum also used the event to highlight the TouchCare Nano ecosystem.

The details: - The 300U pump offers a larger reservoir while keeping a compact, body-worn, tubeless format. - A 200-unit pump may not cover the intended wear time for some people who need more insulin. - People with higher insulin needs may have to change devices every 1.5 to 2 days when reservoir capacity is limited. - More frequent changes can add planning, site management, skin discomfort and treatment fatigue. - The TouchCare Nano ecosystem links the patch pump with the Nano CGM and APGO algorithm for hybrid closed-loop insulin delivery. - The system combines insulin delivery, glucose monitoring, algorithm support and data review. - Medtrum also highlighted smartphone control through the EasyPatch App. - With a compatible smartphone, users can manage key system functions from a device they already carry. - The 300-unit option is already available in selected international markets.

Between the lines: - Medtrum is positioning capacity as a usability issue, not just a technical specification. - The company is also signaling that connected features may matter as much as the pump itself for daily diabetes management. - The Berlin message, “Medtrum macht mehr möglich” — “Medtrum makes more possible,” framed the product as part of a broader push for flexibility and less visible hardware.

What’s next: - The 300U tubeless patch pump is approaching availability in Germany. - Product availability and regulatory status may vary by country or region. - Medtrum says its broader goal is to keep expanding options that fit real-world insulin needs.

The bottom line: - Medtrum is betting that higher-capacity tubeless insulin delivery, paired with CGM and automation, can make pump therapy more practical for a wider set of patients.